MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a preclinical grant by The Michael J. Fox Foundation under the foundation’s Therapeutics Development Initiative 2008 Program. The modest grant amount supports Depomed in the development of novel gastric retentive controlled-release dosage forms of Levodopa/Carbidopa under the hypothesis that Levodopa/Carbidopa’s window of absorption in the upper gastrointestinal tract can be optimized using Depomed’s AcuForm™ technology. Conceptually, gastric retentive controlled-release could smooth out blood level fluctuations of Levodopa/Carbidopa and lead to more consistent efficacy. One of the major unmet needs in the treatment of Parkinson’s Disease, or PD, is inconsistent efficacy and 4-6 times daily dosing of Levodopa/Carbidopa.
